Want to see WHWK full AI Analyst Report?
WHWK Stock Chart & Stats
$4.87
>-$0.01(-0.27%)
At close: 4:00 PM EDT
$4.87
>-$0.01(-0.27%)
Day’s Range― - ―
52-Week Range$1.97 - $5.50
Previous CloseN/A
Volume49.01K
Average Volume (3M)372.58K
Market Cap
$181.86M
Enterprise Value$189.64M
Total Cash (Recent Filing)$189.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 11, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding57,009,010
10 Day Avg. Volume379,811
30 Day Avg. Volume372,583
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market Cap1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-37.93K
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$7.67Price Target Upside57.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal LeverageAn effectively debt-free balance sheet reduces interest obligations and refinancing exposure, giving Whitehawk greater financial flexibility while it develops its pipeline. The larger equity base also provides a capital buffer, although it does not eliminate the pressure from ongoing losses.
Positive Gross Profit In 2025Positive gross profit in 2025 indicates that the business generated some value above direct costs during that period, an important foundation for future operating leverage. However, the benefit remains limited because overall expenses still left the company with substantial losses.
Experienced Oncology LeadershipAdding an oncology leader with more than two decades of global strategy and commercial experience could strengthen oversight and business-development decisions as Whitehawk advances its antibody-drug conjugate portfolio. That expertise may support longer-term development and commercialization planning.
Bears Say
No Current RevenueZero trailing-twelve-month revenue leaves Whitehawk without demonstrated commercial traction and makes the company dependent on future product development to establish an operating business. This weak base limits internal funding capacity and increases execution risk over the next several quarters.
Persistent Large LossesPersistent losses of this magnitude show that current operating costs substantially exceed revenue generation and that profitability is not yet established. Unless revenue improves materially or expenses fall, continued losses can erode the equity base and constrain investment in the pipeline.
Heavy Cash BurnSustained operating and free-cash-flow outflows of roughly $69.3 million indicate that Whitehawk is not close to self-funding its operations. Continued cash burn may require external capital over time, increasing financing dependence and potentially limiting strategic flexibility.
Whitehawk Therapeutics News
WHWK FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was $1.97 and its highest was $5.50 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is $181.86M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 20 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.296 by $0.096.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.22.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 57,009,010 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.296. Following the earnings report the stock price went up 15.479%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in WHWK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Whitehawk Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (57.43% Upside)
$7.67 (57.43% Upside)
Blogger Sentiment
Bullish
WHWK Sentiment 100%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.07%
12-Months-Change
Fundamentals
Return on Equity
-53.89%
Trailing 12-Months
Asset Growth
7.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
WHWK Stock 12 Month Forecast
Average Price Target
$7.67
▲(57.43% Upside)
Technical Analysis
Ownership Overview
26.37% Insiders
3.44% Mutual Funds
61.92% Other Institutional Investors
1.94% Public Companies and
Individual Investors